ÐÂÎÅ×ÊѶ
ÆƾÖÌÇÄò²¡Éö²¡£¡ÓÀÀÖ¸ß60netMCR»·ëÄÁÆ·¨ÁÙ´²Ç°ÁÆЧÏÔÖø
ÈÕÆÚ£º
2026Äê06ÔÂ15ÈÕ 15:43
ÌÇÄò²¡Éö²¡ÊÇʲô £¿
ÌÇÄò²¡Éö²¡£¨diabetic nephropathy£¬DN£©ÊÇÌÇÄò²¡×îÑϳÁºÍ×î³£¼ûµÄ΢Ѫ¹Ü²¢·¢Ö¢Ö®Ò»£¬ÔÚҽѧÉÏÒ²³ÆΪÌÇÄò²¡ÉöÓ×ÇòÓ²»¯Ö¢¡£ËüÊÇÂýÐÔÉöÔಡ£¨chronic kidney disease£¬CKD£©ºÍÖÕÄ©ÆÚÉöÔಡ£¨end stage renal disease, ESRD£©µÄÊ×Òª²¡Òò1¡£Ä¿Ç°£¬ÔÚÎÒ¹úÉõÖÁÈ«ÇòÌÇÄò²¡Éö²¡·¢²¡Âʾù³ÊÉÏÉýÇ÷Ïò¡£
ÌÇÄò²¡Éö²¡ÊÇÓÉÓڳ־øßѪÌÇ״̬µ¼ÖÂÉöÔà½á¹¹ºÍÖ°ÄÜÖð²½ÊÜËðµÄ²¡Àí¹ý³Ì¡£»¼Õß»úÌå´æÔÚ¼«Æ临ÔӵĴúл´íÂÒ£¬Ò»µ©·¢Õ¹µ½ÖÕÄ©½×¶Î£¬ÍùÍù±ÈÆäËûÉöÔ༲²¡Ò½ÖÎÔ½·¢À±ÊÖ¡£ÌÇÄò²¡Éö²¡ÔçÆÚÌصãÐÔŤתÔ̺¬ÉöÓ×ÇòÂ˹ýÂÊÔö¸ß¡¢ÉöÌå»ýÔö´ó£¬Ëæºó³öÏÖ΢Á¿°×µ°°×Äò£¬¼Ì¶ø·¢Õ¹ÎªÁÙ´²µ°°×Äò¡¢ÉöÏËά»¯£¬×îÖÕµ¼ÖÂÉöÖ°ÄܽøÐÐÐÔ½µÂ䣬ֱÖÁÖÕÄ©ÆÚÉöË¥½ß1¡£
£¨Í¼Æ¬ÆðÔ´£ºhttps://www.hjtdsm.com/yiyong/dn£©
¼òÎöÏÖÓÐÁÆ·¨£¬Äܹ»·¢ÏÖ£¬²»×ã¿ÉÄÜÖ±½Ó¡¢Ç¿Á¦×è¶ÏÉöÔàÄÚºÑ×Ö¢ºÍÏËά»¯¹ý³ÌµÄ¶à°ÐµãÒ©ÎÊǵ±Ç°ÌÇÄò²¡Éö²¡Ò½ÖÎÁìÓò×îÖØÒªµÄÁÙ´²Î´Âú×ãÐèÒª¡£
ÓÀÀÖ¸ß60net£¨ÒÔϼò³Æ“ÓÀÀÖ¸ß60net”£©×ÔÖ÷Ñз¢µÄÓ×·Ö×Ó»·ëÄ£¨MCR¶àëÄ£©ÔÚ×Ô¾õÐÍÌÇÄò²¡Éö²¡Ä£ÐÍÓ×Êó——db/dbÓ×ÊóÉÏ»ñµÃÁËÏÔÖøÁÆЧ£¬Í¨¹ý¶à°ÐµãÐͬÔöЧ£¬ÓÐÍû´øÀ´DNµÄÁÙ´²ÐÂÑ¡Ôñ£¡
MCR»·ëÄÁÆЧÏÔÖø
db/dbÓ×ÊóÊÇ×êÑÐÔçÆÚÌÇÄò²¡Éö²¡²¡±äµÄ³£ÓÃÄ£ÐÍ£¬ÆäÓÉÓÚ»ùÒòÍ»±äµ¼ÖÂÊÝËØÊÜÌåÖ°ÄÜȱµã£¬³ýÁË»á³öÏÖ·ÊÅÖ¡¢¸ßѪÌǵÈÖ¢×´£¬¸ÃÄ£ÐÍÓ×Êóͨ³£»¹ÔÚÐÔÃüÔçÆÚ²û·¢³öÏÔÖøµÄÉöÓ×ÇòΣÏÕ£¨·Ê´ó¡¢Ï¸°ûÔö¶àºÍÉöÓ×ÇòÓ²»¯£©£¬Ëæ×Å´ºÇïµÄÔö³¤¶ø¼Ó³Á£¬»¹²û·¢³öÖеÈˮƽµÄµ°°×Äò¡£
ÊÔÑéÁ˾ÖÏÔʾ£¬¾¹ýΪÆÚ8ÖܵÄÒ½ÖΣ¬Óë¿Õȱ¶ÔÕÕ×édb/dbÓ×ÊóÏà±È£¬MCR»·ëĸ߼ÁÁ¿×éÓ×ÊóµÄÌÇÉöÓйØÖ¸±ê¾ùÓÐÏÔÖøµÄ¸ÄÉÆ£º
1¡¢ ¶àÌǺÍÌǵ°°×ˮƽ£ºÏÔÖø½µµÍ×éÖ¯ÖжàÌǺÍÌǵ°°×ˮƽ£»ÓëÄ£ÐÍ×éÏà±È½µÂä·ù¶ÈÔ¼2/3£¬ÓëGLP-1¶àëÄ×éÁÆЧÏ൱£»
2¡¢ ½ºÔµ°°×ˮƽ£º´ó·ù¶È½µµÍ½ºÔµ°°×ˮƽ£¨Ô¼2/3£©£¬Ï÷¼õ½ºÔ³Á»ý£¬ÏÔÖø¸ÄÉÆÉöÔàÏËά»¯Ë®Æ½£¬ÓëGLP-1¶àëÄ×éÁÆЧÏ൱£»
3¡¢ Äòµ°°×ˮƽ£ºÒ½ÖÎ4Öܽ«Äòµ°°×ˮƽ´Ó»ùÏß½µÖÁÒ»°ë¡£
ͼ1. db/dbÓ×ÊóÉöÔಡ±äͼ
G1½¡È«¶ÔÕÕ×é/G2Ä£ÐÍ×é/G3»·ëĵͼÁÁ¿×é/ G4»·ëĸ߼ÁÁ¿×é/G5 GLP-1¶àëÄ×é
MCR»·ëÄ£º¶à°ÐµãÐͬÔöЧ
MCR»·ëÄÔÚÌÇÄò²¡Éö²¡Öвû·¢³öµÄ׿ԽÁÆЧ£¬Ô´ÓÚÆä×÷ΪһÖÖÐͬÐÔË«ÊÜÌ弤°º¼ÁµÄ¹ÖÒìÉè¼Æ¡£¸Ã·Ö×ÓÀûÓÃÆä¹¹ÏóÔ¼ÊøµÄ»·ëĽṹ£¬ÊµÏÖÁ˶ԺÚƤÖÊËØÊÜÌåÑÇÐÍMC1RºÍMC4RµÄ¸ßÇ׺ÍÁ¦¼°Ñ¡ÔñÐÔ¹²¼¤»î¡£
ÕâÖÖË«³Á°ÐÏò×÷ÓÃÒý·¢ÁËÏÔÖøµÄÐͬÔöЧЧӦ£¬¹²Í¬×÷ÓÃÓÚÌÇÄò²¡Éö²¡µÄÖ÷ÌⲡÀí»·½Ú£¬×îÖÕµ¼Öµ°°×Äò¼õÇá¡¢×ãϸ°û±£»¤¼°ÉöÓ×ÇòÂ˹ýÖ°ÄܸÄÉƵȶàά¶È²¡ÀíÖ¸±êµÄÏÔÖøÄæת£¬Õ¹Ê¾Á˶à°Ðµã¹ýÎÊÕ½ÊõÔÚ¸´ÔÓ´úлÐÔ¼²²¡Ò½ÖÎÖеÄ͹ÆðÓÅÊÆ¡£
¼¤»îMC1R£ºÃâÒßµ÷½Ú¿¹Ñ×+ÒÖÔìÏËά»¯¹ý³Ì+Ö±½Ó±£»¤×ãϸ°û
MC1RÖØÒª´æÔÚÓÚƤ·ôÉ«ËØϸ°û¡¢ÃâÒßϸ°ûºÍÉöÔàϸ°û£¨Ô̺¬×ãϸ°ûºÍϵĤϸ°û£©¡£Í¨¹ý¼¤»îMC1R£¬ÏÔÖøÒÖÔìNF-κBµÄ»î»¯£¬Ï÷¼õһϵÁдÙÑ×ϸ°ûÒò×Ó£¨TNF-α¡¢IL-6µÈ£©µÄ²úÉú2 3£»Í¬Ê±Íƽø¿¹Ñ×Òò×Ó£¨ÈçIL-10£©µÄ¿ªÊÍ2 3£¬µ÷½ÚÃâÒßϸ°û£¬¸ÄÉÆÌåÄÚÑ×֢΢»·¾³£¬ÐýתÉöÔà´ÙÑ×״̬¡£
ÉöÔàÏËά»¯£¨Ó²»¯£©Êǵ¼ÖÂÖ°ÄÜʧÂäµÄ×îºóͨ·¡£ÓÐ×êÑÐÅú×¢£¬ºÚƤÖÊËؼ¤°º¼Á±»Ö¤ÊµÄܹ»Þ׿¹´ÙÏËά»¯Òò×Ó£¨ÈçTGF-⣩£¬´Ó¶øÏ÷¼õ½ºÔµ°°×µÈϸ°û±í»ùÖʵĺϳɣ¬ÑÓ»ºÉöÓ×ÇòÓ²»¯ºÍ¼äÖÊÏËά»¯µÄ¹ý³Ì4¡£
×ãϸ°ûÊÇ×é³ÉÉöÔàÂ˹ý·®ÀéµÄ¹Ø¼üϸ°û£¬ÆäΣÏÕºÍÍÑÂäÊǵ°°×ÄòµÄÖØÒªÔÒò¡£Ò»Ð©×êÑÐÖ¸³ö£¬ºÚƤÖÊËؼ¤°º¼ÁÄÜͨ¹ýÖ±½Ó×÷ÓÃÓÚ×ãϸ°ûÉϵÄÊÜÌ壨ÈçMC1R£©£¬²»±äÆäϸ°û¹Ç¼Ü£¬ÒÖÔìµòÍö£¬´Ó¶ø´Ó½á¹¹ÉÏÊØ»¤Â˹ýÖ°ÄܵÄÆëÈ«ÐÔ£¬Ï÷¼õµ°°×Äò5 6¡£
ͼ2. MCRÔÚÉöÔàϸ°ûÖеÄÉ¢²¼5
¼¤»îMC4R£º¸ÄÉÆÒȵºËصֿ¹ºÍ´úл
MC4RÖØÒª´æÔÚÓÚÖÐÊàÉñ¾ÏµÍ³£¬²Î¼Óµ÷½ÚÄÜÁ¿Æ½ºâºÍʳÓû¡£Í¨¹ý¼¤»îMC4R£¬¸ÄÉÆÈ«ÉíÒȵºËØÃô¸ÐÐÔºÍÆÏÌÑÌÇ´úл£¬ÓÐÀûÓÚ´Ó±¾ÔÉÏÒ½ÖÎÌÇÄò²¡Éö²¡——ÌÇÄò²¡¡£
MCR»·ëÄ£º¶à¼²²¡ÁìÓòDZÔÚÀûÓÿÉÄÜÐÔ
Õ°Íû½«À´£¬ÓÀÀÖ¸ß60net½«ÒÔMCR»·ëÄÔÚ¼õ³Á´úлÁìÓò»ñµÃµÄÍ»ÆÆΪ»ùʯ£¬Æ¾½èÆä×÷ÓûúÔìµÄÖ÷ÌâÓÅÊÆ£¬»ý¼«ÍØÕ¹ÖÐÊàÉñ¾ÏµÍ³£¨CNS£©¼°×ÔÌåÃâÒߣ¨×ÔÃ⣩µÈDZÁ¦¾Þ´óµÄÐÂÊÊÓ¦Ö¢ÁìÓò¡£
Êг¡Ô¶¾°ÓëÕ½Êõ²¼¾Ö
È«ÇòÌÇÄò²¡Éö²¡Ò½ÖÎÒ©ÎïÊг¡Õý´¦ÓÚ¼±¾çÔö³¤½×¶Î£¬Ô¼30%-40%µÄÌÇÄò²¡»¼Õ߻ᷢչΪÌÇÄò²¡Éö²¡£¬»¼Õß»ùÊýÖØ´ó¡£2024ÄêÈ«ÇòDNÒ©ÎïÊг¡¹æÄ£ÒÑÍ»ÆÆ120ÒÚÃÀÔª£¬Ô¤¼Æ2030Ä꽫³¬¹ý300ÒÚÃÀÔª£¬Ä긴ºÏÔö³¤ÂÊ´ï12.5%7¡£Öйú×÷ΪȫÇòÌÇÄò²¡»¼Õß×î¶àµÄ¹ú¶È£¬ÕïÁÆÂʵijÖÐøÌáÉýʹÆä³ÉΪ×î¾ßÔöÓÀ»îÁ¦µÄÊг¡Ö®Ò»¡£
Ö»¹ÜÏÖÓг߶ÈÁÆ·¨²»Ðݽø»¯£¬µ«ÉÐÎÞ¿ÉÄÜÄæתÏËά»¯¹ý³ÌµÄÌØÒìÐÔÒ©Îï¡£MCR»·ëÄ´Ó¿¹Ñס¢¿¹ÏËά»¯¡¢´úлµ÷½ÚÈý´óÖ÷Ìâ»·½ÚͬʱȾָ£¬ÓëÏÖÓÐÁÆ·¨ÐγÉÓÅÁ¼»¥²¹£¬ÓÈÆäÔÚ¿¹ÏËά»¯·½Ãæ¾ß±¸¹ÖÒì²î¾à»¯ÓÅÊÆ¡£
Ä¿Ç°£¬¹«Ë¾Ñз¢¹ÜÏßÕýÎȲ½Íƶ¯£¬ºóÐø½«³Áµã·¢Õ¹ÏµÍ³µÄÁÙ´²Ç°Ò©Ð§Ó붾Àíѧ×êÑУ¬ÓйØÖ÷Ì⻯ºÏÎïÒÑ»ñµÃרÀûÊÚȨ£¬¹¹½¨Á˼áʵµÄ¼¼Êõ±ÚÀÝ¡£ÔÚ´ËרÀû¼Ó³ÖÏ£¬ÓÀÀÖ¸ß60net½«È«Á¦¼Ó¿ìÕâÒ»²î¾à»¯¶àëÄÐÂÒ©µÄÑз¢¹ý³Ì£¬Ö¾ÔÚÔçÈÕ½«ÆäÍÆÏòÁÙ´²£¬Ô츣ȫÇò»¼Õߣ¬Í¬Ê±ÇÀÕ¼ÕâǧÒÚÀ¶º£Êг¡µÄÕ½Êõ¸ßµØ¡£
×ÊÁÏÆðÔ´
1.Öйú¹«¼Ò½¡È«Íø£¨2014£©£¬¾ÍÕïÖ¸ÄÏ ³£¼û¼²²¡ ÌÇÄò²¡Éö²¡.http://www.chealth.org.cn/mon/diseases/article/MA144004836.html
2. Wang, W., Guo, D. Y., Lin, Y. J., & Tao, Y. X. (2019). Melanocortin Regulation of Inflammation. Frontiers in endocrinology, 10, 683. https://doi.org/10.3389/fendo.2019.00683
3. Ahmed, T. J., Montero-Melendez, T., Perretti, M., & Pitzalis, C. (2013). Curbing Inflammation through Endogenous Pathways: Focus on Melanocortin Peptides. International journal of inflammation, 2013, 985815. https://doi.org/10.1155/2013/985815
4. ÕŽõ.ºÚƤÖÊËضԾÖÔî½Ú¶ÎÐÔÉöÓ×ÇòÓ²»¯Ö¢µÄÒ½ÖÎ×÷Óü°»úÔì×êÑÐ[D].Ö£ÖÝ´óѧ,2022.DOI:"". http://www.tzsti.com:90/D/Thesis_Y3990408.aspx
5. Chang, M., Chen, B., Shaffner, J., Dworkin, L. D., & Gong, R. (2021). Melanocortin System in Kidney Homeostasis and Disease: Novel Therapeutic Opportunities. Frontiers in physiology, 12, 651236. https://doi.org/10.3389/fphys.2021.651236
6. Luipa Khandker, PhD; Priyanka Dhingra, PhD; John H. Dodd, PhD; Carl Spana, PhD; Paul S. Kayne, PhD. (2023). Melanocortin 1 Receptor (MC1R) Agonist PL8177 Protects Against Podocyte Loss in a Streptozotocin-Induced <br/>Rat Model of Diabetic Nephropathy. 14th Biennial International Podocyte Conference Philadelphia, PA. 2023. https://palatin.com/wp-content/uploads/2023/05/PAL-G23PL8.3015-IPD-2023-Khandker-PL8177-Protects-Against-Podocyte-Loss-Poster-0518-2-OK-TO-PRINT.pdf
7. 2025ÖÁ2030ÌÇÄò²¡Éö²¡ÐÐÒµÔËӪ̬ÊÆÓëͶ×ÊÔ¶¾°µ÷²é×êÑл㱨.https://max.book118.com/html/2025/1022/8123135105010001.shtm
ÓйØÍƼö
ÍøÕ¾½¨É裺ÖÐÆó¶¯Á¦ ̨ÖÝ